Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 32 | 2024 | 896 | 5.870 |
Why?
|
| Anti-HIV Agents | 10 | 2024 | 173 | 2.590 |
Why?
|
| Pre-Exposure Prophylaxis | 7 | 2023 | 164 | 1.850 |
Why?
|
| Mass Screening | 9 | 2024 | 675 | 1.760 |
Why?
|
| Transgender Persons | 4 | 2023 | 117 | 1.510 |
Why?
|
| Continuity of Patient Care | 3 | 2020 | 176 | 1.190 |
Why?
|
| Social Stigma | 4 | 2024 | 76 | 1.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2020 | 74 | 0.930 |
Why?
|
| Sexual and Gender Minorities | 5 | 2022 | 230 | 0.880 |
Why?
|
| Emergency Service, Hospital | 4 | 2024 | 557 | 0.840 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2024 | 102 | 0.800 |
Why?
|
| Homosexuality, Male | 8 | 2022 | 318 | 0.750 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 58 | 0.680 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2019 | 2 | 0.640 |
Why?
|
| Pandemics | 9 | 2023 | 807 | 0.640 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 59 | 0.630 |
Why?
|
| Antitubercular Agents | 1 | 2019 | 62 | 0.620 |
Why?
|
| Chicago | 10 | 2024 | 1463 | 0.620 |
Why?
|
| Abscess | 1 | 2019 | 95 | 0.610 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2019 | 59 | 0.610 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.610 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 111 | 0.560 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 158 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 270 | 0.530 |
Why?
|
| Health Equity | 1 | 2019 | 98 | 0.510 |
Why?
|
| AIDS Serodiagnosis | 3 | 2022 | 27 | 0.510 |
Why?
|
| Humans | 44 | 2024 | 92351 | 0.490 |
Why?
|
| Qualitative Research | 4 | 2024 | 325 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 315 | 0.460 |
Why?
|
| Retrospective Studies | 13 | 2024 | 9694 | 0.460 |
Why?
|
| Rilpivirine | 2 | 2024 | 2 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1075 | 0.440 |
Why?
|
| Pyridones | 2 | 2024 | 59 | 0.430 |
Why?
|
| Adult | 24 | 2024 | 27547 | 0.430 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 443 | 0.430 |
Why?
|
| Syphilis | 2 | 2024 | 34 | 0.420 |
Why?
|
| Male | 25 | 2024 | 43928 | 0.410 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 70 | 0.390 |
Why?
|
| Young Adult | 12 | 2024 | 6629 | 0.390 |
Why?
|
| Hospitals, Urban | 2 | 2024 | 64 | 0.390 |
Why?
|
| Female | 24 | 2024 | 47901 | 0.380 |
Why?
|
| Interviews as Topic | 5 | 2024 | 351 | 0.360 |
Why?
|
| Middle Aged | 16 | 2024 | 27045 | 0.350 |
Why?
|
| Contact Tracing | 2 | 2021 | 29 | 0.340 |
Why?
|
| Risk Factors | 5 | 2021 | 5708 | 0.340 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 84 | 0.300 |
Why?
|
| United States | 10 | 2024 | 7367 | 0.290 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 399 | 0.290 |
Why?
|
| Medication Adherence | 3 | 2024 | 147 | 0.250 |
Why?
|
| Social Networking | 3 | 2021 | 78 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 542 | 0.230 |
Why?
|
| Focus Groups | 2 | 2023 | 186 | 0.230 |
Why?
|
| Gonorrhea | 1 | 2024 | 23 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2024 | 32 | 0.220 |
Why?
|
| Adolescent | 9 | 2024 | 9495 | 0.210 |
Why?
|
| Coinfection | 3 | 2024 | 63 | 0.200 |
Why?
|
| Midwestern United States | 1 | 2023 | 85 | 0.200 |
Why?
|
| Azithromycin | 2 | 2020 | 13 | 0.200 |
Why?
|
| Epidemics | 1 | 2023 | 33 | 0.200 |
Why?
|
| Influenza, Human | 2 | 2016 | 343 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 2 | 2022 | 31 | 0.190 |
Why?
|
| Residential Treatment | 1 | 2021 | 5 | 0.180 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 145 | 0.180 |
Why?
|
| Mycobacterium chelonae | 1 | 2021 | 4 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 276 | 0.180 |
Why?
|
| HIV | 1 | 2021 | 48 | 0.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 28 | 0.180 |
Why?
|
| Trust | 1 | 2021 | 98 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 11 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 80 | 0.170 |
Why?
|
| San Francisco | 3 | 2024 | 25 | 0.170 |
Why?
|
| Cephalosporins | 1 | 2020 | 24 | 0.170 |
Why?
|
| Occupational Exposure | 1 | 2021 | 88 | 0.170 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.170 |
Why?
|
| Psychotherapy, Brief | 1 | 2020 | 13 | 0.160 |
Why?
|
| Sexual Partners | 1 | 2020 | 104 | 0.160 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 133 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 148 | 0.150 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.150 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 15 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 54 | 0.150 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 36 | 0.150 |
Why?
|
| Cross Reactions | 1 | 2018 | 110 | 0.150 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 37 | 0.150 |
Why?
|
| Carrier State | 1 | 2018 | 39 | 0.150 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 13 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 202 | 0.150 |
Why?
|
| Patient Participation | 2 | 2022 | 227 | 0.150 |
Why?
|
| Research Design | 2 | 2020 | 600 | 0.150 |
Why?
|
| Staphylococcal Infections | 2 | 2018 | 280 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2018 | 220 | 0.150 |
Why?
|
| Telemedicine | 1 | 2022 | 213 | 0.150 |
Why?
|
| Heterosexuality | 1 | 2018 | 21 | 0.150 |
Why?
|
| Research Personnel | 1 | 2019 | 76 | 0.140 |
Why?
|
| Prevalence | 1 | 2022 | 1298 | 0.140 |
Why?
|
| Alcoholism | 1 | 2020 | 185 | 0.140 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 59 | 0.140 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 247 | 0.140 |
Why?
|
| Acute Disease | 1 | 2020 | 855 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 181 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2020 | 353 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 424 | 0.130 |
Why?
|
| Students, Medical | 1 | 2022 | 434 | 0.130 |
Why?
|
| Soft Tissue Infections | 1 | 2015 | 26 | 0.120 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2015 | 25 | 0.120 |
Why?
|
| Virus Diseases | 1 | 2016 | 99 | 0.120 |
Why?
|
| Models, Psychological | 1 | 2016 | 161 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 329 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2730 | 0.120 |
Why?
|
| Diketopiperazines | 2 | 2024 | 2 | 0.110 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 108 | 0.110 |
Why?
|
| Bacterial Infections | 1 | 2016 | 185 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 470 | 0.110 |
Why?
|
| Delayed-Action Preparations | 2 | 2024 | 112 | 0.110 |
Why?
|
| Injections | 2 | 2024 | 119 | 0.110 |
Why?
|
| Comorbidity | 3 | 2021 | 986 | 0.090 |
Why?
|
| Public Health | 2 | 2023 | 146 | 0.090 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2011 | 22 | 0.090 |
Why?
|
| Aged | 5 | 2021 | 19952 | 0.090 |
Why?
|
| Contraceptive Agents, Female | 1 | 2011 | 30 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 680 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2020 | 8730 | 0.080 |
Why?
|
| Religion and Medicine | 1 | 2011 | 121 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2020 | 2368 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 452 | 0.070 |
Why?
|
| Infant | 3 | 2018 | 3206 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 3806 | 0.060 |
Why?
|
| Georgia | 1 | 2024 | 40 | 0.050 |
Why?
|
| Incidence | 2 | 2018 | 1661 | 0.050 |
Why?
|
| Risk Management | 1 | 2021 | 43 | 0.040 |
Why?
|
| Child | 3 | 2018 | 7309 | 0.040 |
Why?
|
| Cities | 1 | 2021 | 52 | 0.040 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 186 | 0.040 |
Why?
|
| Needle Sharing | 1 | 2020 | 15 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 52 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 316 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 147 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 89 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 610 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2016 | 2506 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 1239 | 0.040 |
Why?
|
| Homophobia | 1 | 2019 | 4 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 115 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 365 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 2018 | 9 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 320 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2018 | 55 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 77 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 173 | 0.040 |
Why?
|
| Plasmids | 1 | 2018 | 288 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 902 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 488 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2018 | 152 | 0.030 |
Why?
|
| Perception | 1 | 2018 | 183 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1194 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 228 | 0.030 |
Why?
|
| Racism | 1 | 2019 | 96 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 364 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 2979 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 658 | 0.030 |
Why?
|
| Gender Identity | 1 | 2016 | 55 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1773 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1094 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2015 | 62 | 0.030 |
Why?
|
| Minority Groups | 1 | 2016 | 151 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 206 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 152 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 1865 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 215 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 437 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 201 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2009 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 863 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 808 | 0.030 |
Why?
|
| Phylogeny | 1 | 2018 | 1231 | 0.030 |
Why?
|
| Critical Care | 1 | 2016 | 397 | 0.020 |
Why?
|
| Hospitals | 1 | 2015 | 313 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1512 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 429 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2015 | 498 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 630 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3775 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2011 | 159 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 925 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 995 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6918 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 3113 | 0.010 |
Why?
|